Back to News
Market Impact: 0.35
Acadia Drug Misses Primary Goal in Alzheimer's Related Psychosis
Source: benzinga.com
Healthcare & BiotechCompany Fundamentals
Acadia Pharmaceuticals shares traded lower Thursday after the company released topline Phase 2 results from its RADIANT clinical-trial program for remlifanserin in Alzheimer's disease psychosis. The market reaction signals investor disappointment or uncertainty around the trial update, though no efficacy, safety, or financial details were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
ACAD-0.45
More News
- Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data
- Oracle Japan shares surge 7% after record fiscal first quarter, bucking selloff of U.S. parent
- Costco makes progress on a key membership metric. Here's our new price target on the stock
- Akamai secures $11.6B cloud deal with Anthropic for AI workloads
- Here’s the Tesla Semi… again
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly